More Changes In Carcinogenesis Program At NCI: Gori, Workshops Out, Branch Chiefs Running It
In Brief: NCI Can Proceed With Grant, Contract Awards At Full FY 1978 Level; Rundles Heads ACS
Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans
First analysis From Profiles Reveal New Data On Centers
New research Suggested For Immunobiology
NCI Offers Chlorozotocin
To Industry for Development, NDA
Drug Development Gets Extra $500,000
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”
